Muconil Oral Liquid 30mg/5ml

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

Ambroxol Hydrochloride

Boleh didapati daripada:

HOE PHARMACEUTICALS SDN. BHD.

INN (Nama Antarabangsa):

Ambroxol Hydrochloride

Unit dalam pakej:

90ml mL

Dikeluarkan oleh:

HOE PHARMACEUTICALS SDN. BHD.

Risalah maklumat

_ CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
_ _
MUCONIL ORAL LIQUID 30MG/5ML
Ambroxol Hydrochloride (30mg/5ml)
1
_ _
WHAT IS IN THIS LEAFLET?
1.
What MUCONIL is used for?
2.
How MUCONIL works?
3.
Before you use MUCONIL
4.
How to use MUCONIL
5.
While you are using
MUCONIL
6.
Side effects
7.
Storage and Disposal of
MUCONIL
8.
Product description
9.
Manufacturer and Product
Registration Holder
10.
Date of Revision
This leaflet answers some common
questions about MUCONIL. It does
not
contain
all
the
available
information.
It
does
not
take
the
place of talking to your pharmacist
or doctor.
All
medicines
have
risks
and
benefits. Your pharmacist or doctor
has weighed the risks of you taking
MUCONIL against the benefits they
expect it will have for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING
THIS
MEDICINE,
ASK
YOUR
PHARMACIST OR DOCTOR.
KEEP
THIS
LEAFLET
WITH
THE
MEDICINE.
You may need to read it again.
WHAT MUCONIL IS USED FOR?
MUCONIL
is
used
in
conditions
where
there
are
a
lot
of
thick
secretions
or
mucus
in
your
air
passages.
HOW MUCONIL WORKS?
MUCONIL
contains
ambroxol
hydrochloride, which helps to clear
the chest by thinning the mucus in
your air passage.
BEFORE YOU USE MUCONIL
_When you must not use it _
Do not take MUCONIL if you are
allergic to ambroxol or to any of the
other ingredients in MUCONIL.
If this applies to you talk to your
pharmacist.
Do not take MUCONIL if you have
hereditary fructose intolerance.
_Before you start to use it _
Tell your pharmacist or doctor if
you have:

Liver problems

Kidney problems
_Taking other medicines _
Taking
of
Muconil
together
with
antibiotics (amoxicillin, cefuroxime,
erythromycin)
drives
to
higher
antibiotic concentration in the lung
tissue.
It is important to tell your doctor or
pharmacist
if
you
are
taking
any
other
medicines, obtained
with or
without a doctor’s prescription.
HOW TO USE MUCONIL
_How much to use _
Adult and children over 12 years:
10ml (2 teaspoons) 2 times daily.
For
children
under
12
years
the
following
dosage
regimen
is
recommended.
C

Ciri produk

MUCONIL ORAL LIQUID 30MG/5ML
Ambroxol Hydrochloride 30mg/5ml Oral Liquid
DESCRIPTION:
A
clear
orange
coloured
liquid
with
orange
flavour.
Each
5ml
contains
Ambroxol
Hydrochloride 30mg with Sodium Benzoate 0.2% w/v as preservative.
PHARMACODYNAMICS:
Ambroxol is an active N-desmethyl metabolite of mucolytic bromhexine.
Preclinically,
ambroxol has been shown to increase the quantity and decrease the
viscosity of respiratory
tract secretions. It enhances pulmonary surfactant production
(surfactant activator) and
stimulates ciliary motility. These actions result in improved mucus
flow and transport
(mucociliary clearance). Improvement of mucociliary clearance has been
shown in clinical
pharmacologic
studies.
Enhancement
of
fluid
secretion
and
mucociliary
clearance
facilitates expectoration and eases cough.
A local anaesthetic effect of ambroxol has been observed in animals
(rabbit) which may be
explained by the sodium channel blocking properties. It was shown in
vitro that ambroxol
blocks neuronal sodium channels; binding was reversible and
concentration-dependent.
Clinical
efficacy
studies
for
the
treatment
with
ambroxol
of
upper
respiratory
tract
symptoms
have
shown
rapid
relief
of
pain
and
pain
related
discomfort
in
the
ear-nose-trachea region upon inhalation.
Cytokine release from blood but also tissue-bound mononuclear and
polymorphonuclear
cells was found to be significantly reduced by ambroxol in vitro.
Following
the
administration
of
ambroxol,
antibiotic
concentrations
(amoxicilline,
cefuroxime,
erythromycin)
in
bronchopulmonary
secretions
and
in
the
sputum
are
increased.
PHARMACOKINETICS:
Absorption of all non-delayed oral forms of ambroxol hydrochloride is
rapid and complete,
with dose linearity in the therapeutic range.
Maximum plasma levels are reached within 1 to 2.5 hours following oral
administration of
the immediate - release formulation and after a median of 6.5 hours of
the slow release
formulation.
The absolute bioavailablility after a 30 mg tablet was found to be
70-80%.
The slow release capsu